 NeuroSense Therapeutics Ltd NASDAQ: NRSN shares are soaring Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate a pharmacokinetic study of PrimeC in healthy adult subjects. PrimeC is designed to synergistically target. 